Skip to main content
Download PDF

Convection-enhanced delivery in the treatment of epilepsy

Neurotherapeutics volume 6, pages 344–351 (2009)Cite this article

Summary

Convection-enhanced delivery (CED) is a novel drug-delivery technique that uses positive hydrostatic pressure to deliver a fluid containing a therapeutic substance by bulk flow directly into the interstitial space within a localized region of the brain parenchyma. CED circumvents the blood-brain barrier and provides a wider, more homogenous distribution than bolus deposition (focal injection) or other diffusion-based delivery approaches. A potential use of CED is for the local delivery of antiseizure agents, which would provide an epilepsy treatment approach that avoids the systemic toxicities of orally administered antiepileptic drugs and bystander effects on non-epileptic brain regions. Recent studies have demonstrated that brief CED infusions of nondiffusible peptides that inhibit the release of excitatory neurotransmitters, including ω-conotoxins and botulinum neurotoxins, can produce long-lasting (weeks to months) seizure protection in the rat amygdala-kindling model. Seizure protection is obtainable without detectable neurological or behavioral side effects. Although conventional diffusible antiepileptic drugs do confer seizure protection when administered locally by CED, the effect is transitory. CED is a potential approach for seizure protection that could represent an alternative to resective surgery in the treatment of focal epilepsies that are resistant to orally-administered antiepileptic drugs. The prolonged duration of action of nondiffusible toxins would allow seizure protection to be maintained chronically with infrequent reinfusions.

References

  1. Nilsen KE, Cock HR. Focal treatment for refractory epilepsy: hope for the future? Brain Res Brain Res Rev 2004;44: 141–153.

    Article  PubMed  Google Scholar 

  2. Fisher RS, Chen DK. New routes for delivery of anti-epileptic medications. Acta Neurol Taiwan 2006;15: 225–231.

    PubMed  Google Scholar 

  3. Barcia JA, Gallego JM. Intraventricular and intracerebral delivery of anti-epileptic drugs in the kindling model. Neurotherapeutics 2009;6: 337–343.

    CAS  Article  PubMed  Google Scholar 

  4. Anschel DJ, Ortega EL, Kraus AC, Fisher RS. Focally injected adenosine prevents seizures in the rat. Exp Neurol 2004;190: 544–547.

    CAS  Article  PubMed  Google Scholar 

  5. Fiandaca MS, Forsayeth JR, Dickinson PJ, Bankiewicz KS. Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics 2008;5: 123–127.

    Article  PubMed  Google Scholar 

  6. Ludvig N, Kuzniecky RI, Baptiste SL, et al. Epidural pentobarbital delivery can prevent locally induced neocortical seizures in rats: the prospect of transmeningeal pharmacotherapy for intractable focal epilepsy. Epilepsia 2006;47: 1792–1802.

    Article  PubMed  Google Scholar 

  7. John JE, Baptiste SL, Sheffield LG, et al. Transmeningeal delivery of GABA to control neocortical seizures in rats. Epilepsy Res 2007;75: 10–17.

    CAS  Article  PubMed  Google Scholar 

  8. Ludvig N, Baptiste SL, Tang HM, et al. Localized transmeningeal muscimol prevents neocortical seizures in rats and nonhuman primates: therapeutic implications. Epilepsia 2008 Dec 2 [Epub ahead of print].

  9. Kokaia M, Aebischer P, Elmér E, et al. Seizure suppression in kindling epilepsy by intracerebral implants of GABA- but not by noradrenaline-releasing polymer matrices. Exp Brain Res 1994; 100: 385–394.

    CAS  Article  PubMed  Google Scholar 

  10. Kubek M, Liang D, Byrd K, Domb A. Prolonged seizure suppression by a single implantable polymeric-TRH microdisk preparation. Brain Res 1998;809: 189–197.

    CAS  Article  PubMed  Google Scholar 

  11. Tamargo RJ, Rossell LA, Kossoff EH, Tyler BM, Ewend MG, Aryanpur JJ. The intracerebral administration of phenytoin using controlled-release polymers reduces experimental seizures in rats. Epilepsy Res 2002;48: 145–155.

    CAS  Article  PubMed  Google Scholar 

  12. López T, Ortiz E, Quintana P, González RD. A nanostructured titania bioceramic implantable device capable of drug delivery to the temporal lobe of the brain. Colloids Surf A: Physicochem Eng Asp 2007;300: 3–10.

    Article  Google Scholar 

  13. McCown TJ. Adeno-associated virus-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity in vivo. Mol Ther 2006;14: 63–68.

    CAS  Article  PubMed  Google Scholar 

  14. Noè F, Pool AH, Nissinen J, et al. Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain 2008;131(pt 6): 1506–1515.

    Article  PubMed  Google Scholar 

  15. Carpentino JE, Hartman NW, Grabel LB, Naegele JR. Region-specific differentiation of embryonic stem cell-derived neural progenitor transplants into the adult mouse hippocampus following seizures. J Neurosci Res 2008;86: 512–524.

    CAS  Article  PubMed  Google Scholar 

  16. Noé F, Frascal A, Balducci C, et al. Neuropeptide Y overexpression using recombinant adenoassociated viral vectors. Neurotherapeutics 2009;6: 300–306.

    Article  PubMed  Google Scholar 

  17. McCown TJ. Adeno-associated virus vector-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity. Neurotherapeutics 2009;6: 307–311.

    CAS  Article  PubMed  Google Scholar 

  18. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Old-field EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994;91: 2076–2080.

    CAS  Article  PubMed  Google Scholar 

  19. Lieberman DM, Laske DW, Morrison PF, Bankiewicz KS, Oldfield EH. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 1995;82: 1021–1029.

    CAS  Article  PubMed  Google Scholar 

  20. Haroun RI, Brem H. Local drug delivery. Curr Opin Oncol 2000; 12: 187–193.

    CAS  Article  PubMed  Google Scholar 

  21. Lonser RR, Walbridge S, Garmestani K, et al. Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg 2002;97: 905–913.

    Article  PubMed  Google Scholar 

  22. MacKay JA, Deen DF, Szoka FC Jr. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res 2005;1035: 139–153.

    CAS  Article  PubMed  Google Scholar 

  23. Morrison PF, Laske DW, Bobo H, Oldfield EH, Dedrick RL. High-flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol 1994;266(1 pt 2): R292-R305.

    CAS  PubMed  Google Scholar 

  24. Sampson JH, Raghavan R, Brady ML, et al. Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol 2007;9: 343–353.

    CAS  Article  PubMed  Google Scholar 

  25. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 1997;3: 1362–1368.

    CAS  Article  PubMed  Google Scholar 

  26. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 2000;6: 2157–2165.

    CAS  PubMed  Google Scholar 

  27. Voges J, Reszka R, Gossmann A, et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 2003;54: 479–487.

    CAS  Article  PubMed  Google Scholar 

  28. Lidar Z, Mardor Y, Jonas T, et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 2004;100: 472–479.

    CAS  Article  PubMed  Google Scholar 

  29. Sampson JH, Akabani G, Archer GE, et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol 2008;10: 320–329.

    CAS  Article  PubMed  Google Scholar 

  30. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003;9: 589–595.

    CAS  Article  PubMed  Google Scholar 

  31. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006;59: 459–466.

    CAS  Article  PubMed  Google Scholar 

  32. Patel NK, Gill SS. GDNF delivery for Parkinson’s disease. Acta Neurochir Suppl 2007;97(pt 2): 135–154.

    CAS  Article  PubMed  Google Scholar 

  33. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet 2007; 369: 2097–2105.

    CAS  Article  PubMed  Google Scholar 

  34. Marks WJ Jr, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase I trial. Lancet Neurol 2008;7: 400–408.

    Article  PubMed  Google Scholar 

  35. Kaplitt MG, During MJ, inventors. Infusion device and method for infusing material into the brain of a patient. US patent application 2006;0129126 A1 (application 11/280,965).

  36. Krauze MT, Saito R, Noble C, et al. Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg 2005; 103: 923–939.

    Article  PubMed  Google Scholar 

  37. Neeves KB, Lo CT, Foley CP, Saltzman WM, Olbricht WL. Fabrication and characterization of microfluidic probes for convection enhanced drug delivery. J Control Release 2006;111: 252–362.

    CAS  Article  PubMed  Google Scholar 

  38. Ai Y, Markesbery W, Zhang Z, Grondin R, Elseberry D, Gerhardt GA, Gash DM. Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J Comp Neurol 2003;461: 250–261.

    CAS  Article  PubMed  Google Scholar 

  39. Bennewitz MF, Saltzman WM. Nanotechnology for the delivery of drugs to the brain for epilepsy. Neurotherapeutics 2009;6: 323–336.

    CAS  Article  PubMed  Google Scholar 

  40. Richardson RM, Larson PS, Bankiewicz KS. Gene and cell delivery to the degenerated striatum: status of preclinical efforts in primate models. Neurosurgery 2008;63: 629–644.

    Article  PubMed  Google Scholar 

  41. Smith DC, Krahl SE, Browning RA, Barea EJ. Rapid cessation of focally induced generalized seizures in rats through micro-infusion of lidocaine hydrochloride into the focus. Epilepsia 1993;34: 43–53.

    CAS  Article  PubMed  Google Scholar 

  42. Eder HG, Stein A, Fisher RS. Interictal and ictal activity in the rat cobalt/pilocarpine model of epilepsy decreased by local perfusion of diazepam. Epilepsy Res 1997;29: 17–24.

    CAS  Article  PubMed  Google Scholar 

  43. Eder HG, Jones DB, Fisher RS. Local perfusion of diazepam attenuates interictal and ictal events in the bicuculline model of epilepsy in rats. Epilepsia 1997;38: 516–521.

    CAS  Article  PubMed  Google Scholar 

  44. Stein AG, Eder HG, Blum DE, Drachev A, Fisher RS. An automated drug delivery system for focal epilepsy. Epilepsy Res 2000; 39: 103–114.

    CAS  Article  PubMed  Google Scholar 

  45. Gasior M, White NA, Rogawski MA. Prolonged attenuation of amygdala-kindled seizure measures in rats by convection-enhanced delivery of the N-type calcium channel antagonists ω-conotoxin GVIA and ω-conotoxin MVIIA. J Pharmacol Exp Ther 2007; 323: 458–468.

    CAS  Article  PubMed  Google Scholar 

  46. Heiss JD, Walbridge S, Morrison P, et al. Local distribution and toxicity of prolonged hippocampal infusion of muscimol. J Neurosurg 2005;103: 1035–1045.

    CAS  Article  PubMed  Google Scholar 

  47. Bowersox SS, Luther R. Pharmacotherapeutic potential of ω-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus. Toxicon 1998;36: 1651–1658.

    CAS  Article  PubMed  Google Scholar 

  48. Westenbroek RE, Hell JW, Warner C, Dubel SJ, Snutch TP, Catterall WA. Biochemical properties and subcellular distribution of an N-type calcium channel α1 subunit. Neuron 1992;9: 1099–1115.

    CAS  Article  PubMed  Google Scholar 

  49. Boulton CL, O’Shaughnessy CT. The effect of calcium channel antagonists on spontaneous and evoked epileptiform activity in the rat neocortex in vitro. Eur J Neurosci 1991;3: 992–1000.

    Article  PubMed  Google Scholar 

  50. Jackson HC, Scheideler MA. Behavioural and anticonvulsant effects of Ca2+ channel toxins in DBA/2 mice. Psychopharmacology (Berl) 1996;126: 85–90.

    CAS  Article  Google Scholar 

  51. van Luijtelaar G, Wiadema D, Elants C, Scheenen W. Opposite effects of T- and L-type Ca2+ channels blockers in generalized absence epilepsy. Eur J Pharmacol 2000;406: 381–389.

    Article  PubMed  Google Scholar 

  52. Wang S, Ding M, Wu D, Zhan J, Chen Z. ω-Conotoxin MVIIA inhibits amygdaloid kindled seizures in Sprague-Dawley rats. Neurosci Lett 2007;413: 163–167.

    CAS  Article  PubMed  Google Scholar 

  53. Williams JA, Day M, Heavner JE. Ziconotide: an update and review. Expert Opin Pharmacother 2008;9: 1575–1583.

    CAS  Article  PubMed  Google Scholar 

  54. Verderio C, Pozzi D, Pravettoni E, et al. SNAP-25 modulation of calcium dynamics underlies differences in GABAergic and glutamatergic responsiveness to depolarization. Neuron 2004; 41: 599–610.

    CAS  Article  PubMed  Google Scholar 

  55. Matteoli M, Pozzi D, Grumelli C, et al. The synaptic split of SNAP-25: Different roles in glutamatergic and GABAergic neurons? Neuroscience 2009; 158: 223–230.

    CAS  Article  PubMed  Google Scholar 

  56. Verderio C, Grumelli C, Raiteri L, et al. Traffic of botulinum toxins A and E in excitatory and inhibitory neurons. Traffic 2007;8: 142–153.

    CAS  Article  PubMed  Google Scholar 

  57. Costantin L, Bozzi Y, Richichi C, et al. Antiepileptic effects of botulinum neurotoxin E. J Neurosci 2005;25: 1943–1951.

    CAS  Article  PubMed  Google Scholar 

  58. Bozzi Y, Costantin L, Antonucci F, Caleo M. Action of botulinum neurotoxins in the central nervous system: antiepileptic effects. Neurotox Res 2006;9: 197–203.

    CAS  Article  PubMed  Google Scholar 

  59. Cohen-Gadol AA, Wilhelmi BG, Collignon F, et al. Long-term outcome of epilepsy surgery among 399 patients with nonlesional seizure foci including mesial temporal lobe sclerosis. J Neurosurg 2006;104: 513–524.

    Article  PubMed  Google Scholar 

  60. Pace JR, Lonser RR, Kirkby RD, Jeffries N, Rogawski MA, Oldfield EH. Epileptiform activity extinguished by amygdala infusion of the neurotoxin ibotenate in a rat model of temporal lobe epilepsy. J Neurosurg 2002;97: 450–454.

    CAS  Article  PubMed  Google Scholar 

  61. Wiley RG, Kline IV RH. Neuronal lesioning with axonally transported toxins. J Neurosci Methods 2000; 103: 73–82.

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Neurology, School of Medicine, University of California, Davis, 4860 Y Street, Suite 3700, 95817-2307, Sacramento, California

    Michael A. Rogawski

Authors
  1. Michael A. Rogawski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael A. Rogawski.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Rogawski, M.A. Convection-enhanced delivery in the treatment of epilepsy. Neurotherapeutics 6, 344–351 (2009). https://doi.org/10.1016/j.nurt.2009.01.017

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1016/j.nurt.2009.01.017

Key Words

  • Convection-enhanced delivery
  • drug delivery
  • ω-conotoxin
  • botulinum neurotoxin
  • kindling
  • antiepileptic drug
  • epilepsy
  • seizure